加壓腹腔氣霧化療（PIPAC）是一種用於腹膜轉移（PM）患者的新型微創藥物遞送系統。先前的第一期研究已證明其為一種安全且可行的紓緩治療替代方案。目前關於其在亞洲人群中可行性、療效及耐受性的證據有限。
適應症：Peritoneal Metastases
收案條件
納入條件
- ≥18 years of old;
- WHO performance of status 0-1;
- Histologically or cytologically proven PM of a gastric, pancreatic or colorectal carcinoma;
- Treatment naïve patients as first-line treatment;
- Progression on or intolerance to first-line systemic chemotherapy as second-line treatment;
- No symptoms of gastrointestinal obstruction;
- No contraindications for the planned systemic therapy or laparoscopy;
- No previous PIPAC/IP/HIPEC;
- No other concurrent malignancies or any other malignancy within 6 months prior to enrolment;
- Able to give written informed consent.
排除條件
- A history of allergic reaction to platinum containing compounds or doxorubicin;
- Pregnant or breastfeeding;
- Any extra-peritoneal metastases;
- Renal impairment, defined as GFR less than 40 mL/min;
- Impaired liver function defined as bilirubin over 1.5 × UNL;
- Inadequate haematological function
- Leucocyte \< 3.00 × 109/L
- Absolute neutrophil counts \< 1.50 × 109/L
- Platelet \< 100 × 109/L
收案條件維持 ClinicalTrials.gov 原始英文登錄資料，實際收案資格以研究團隊的正式評估與受試者同意書為準。資料來源：ClinicalTrials.gov，每兩週自動更新，最後同步：2026年10月8日。